Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Afsaneh Barzi, MD

    TitleAssistant Professor of Clinical Medicine
    SchoolKeck School of Medicine of USC
    DepartmentMedicine
    AddressNOR 3440
    Health Sciences Campus
    Los Angeles California 90089-9172
    Phone+1 323 865 3829
    Emailafsaneh.barzi@med.usc.edu
    vCardDownload vCard
      Other Positions
      TitleMedical Director


      Collapse Overview 
      Collapse Overview
      Barzi earned her M.D. from Tehran University of Medical Sciences, then went on to earn a Master’s in Health Informatics and a Doctorate in Public Health Management and Policy Sciences from the University of Texas Health Science Center in Houston. She recently completed a fellowship in hematology and oncology at the Cleveland Clinic’s Taussig Cancer Center.

      Her research interests are the development of new cancer therapies as well as healthcare economics and metrics of healthcare quality for improving patient care. Dr. Barzi has proposed a phase II study to investigate the overall survival benefit of adding lapatinib to docetaxel in a second line setting in patients with trastuzumab-resistant, HER2-positive gastric cancer.

      “Delivery of personalized treatment to gastric cancer patients has lagged behind other diseases,” Barzi says. “My goal is to establish a second-line treatment for these patients that are HER2-positive and to better understand the mechanisms of resistance to HER2-targeted therapy, paving the way for new therapies that can overcome that resistance.”


      Collapse Biography 
      Collapse Clinical Trials
      Collapse Awards and Honors
      National Cancer Institute2013Travel Award for Markers in Cancer
      Southwest Oncology Group2011Young Investigator Award

      Collapse ORNG Applications 
      Collapse Websites
      Collapse Required Scholarly Project Mentor

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Okazaki S, Schirripa M, Loupakis F, Cao S, Zhang W, Yang D, Ning Y, Berger MD, Miyamoto Y, Suenaga M, Iqubal S, Barzi A, Cremolini C, Falcone A, Battaglin F, Salvatore L, Borelli B, Helentjaris TG, Lenz HJ. Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Cancer. 2017 Jul 14. PMID: 28708932.
        View in: PubMed
      2. Ricker CN, Hanna DL, Peng C, Nguyen NT, Stern MC, Schmit SL, Idos GE, Patel R, Tsai S, Ramirez V, Lin S, Shamasunadara V, Barzi A, Lenz HJ, Figueiredo JC. DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer. Cancer. 2017 Oct 01; 123(19):3732-3743. PMID: 28640387.
        View in: PubMed
      3. Schirripa M, Zhang W, Heinemann V, Cao S, Okazaki S, Yang D, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Gopez RF, West JD, Hanna D, Barzi A, Falcone A, Stintzing S, Lenz HJ. Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. Int J Cancer. 2017 Jul 15; 141(2):383-392. PMID: 28369940.
        View in: PubMed
      4. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Murgioni S, Rossini D, Marmorino F, Mennitto A, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Yamaguchi T, Loupakis F, Lenz HJ. Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. Ann Oncol. 2017 05 01; 28(5):1015-1022. PMID: 28453695.
        View in: PubMed
      5. Barzi A, Klein EA, Daneshmand S, Gill I, Quinn DI, Sadeghi S. Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. Urol Oncol. 2017 Jul; 35(7):459.e15-459.e24. PMID: 28284890.
        View in: PubMed
      6. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017 May 06; 67(3):177-193. PMID: 28248415.
        View in: PubMed
      7. Barzi A, Lenz HJ, Quinn DI, Sadeghi S. Comparative effectiveness of screening strategies for colorectal cancer. Cancer. 2017 May 01; 123(9):1516-1527. PMID: 28117881.
        View in: PubMed
      8. Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res. 2017 Jul 15; 23(14):3657-3666. PMID: 28096270.
        View in: PubMed
      9. Lee E, Liu L, Zhang J, Stern MC, Barzi A, Hwang A, Kim AE, Hamilton AS, Wu AH, Deapen D. Stomach Cancer Disparity among Korean Americans by Tumor Characteristics: Comparison with Non-Hispanic Whites, Japanese Americans, South Koreans, and Japanese. Cancer Epidemiol Biomarkers Prev. 2017 Apr; 26(4):587-596. PMID: 27908922.
        View in: PubMed
      10. Sebio A, Stintzing S, Heinemann V, Sunakawa Y, Zhang W, Ichikawa W, Tsuji A, Takahashi T, Parek A, Yang D, Cao S, Ning Y, Stremitzer S, Matsusaka S, Okazaki S, Barzi A, Berger MD, Lenz HJ. A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J. 2016 Oct 04. PMID: 27698403.
        View in: PubMed
      11. Berger MD, Yang D, Sunakawa Y, Zhang W, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Lenz AM, Bohanes P, Barzi A, Figueiredo JC, Hanna DL, Lenz HJ. Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. Oncotarget. 2016 Aug 16; 7(33):53668-53678. PMID: 27449091.
        View in: PubMed
      12. Shabihkhani M, Yu SS, Yang D, Lin S, Hamilton AS, Lenz HJ, Barzi A. Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population. Clin Colorectal Cancer. 2016 Dec; 15(4):e221-e227. PMID: 27553907.
        View in: PubMed
      13. Barzi A, Klein EA, Dorff TB, Quinn DI, Sadeghi S. Prostatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancer. Prostate Cancer Prostatic Dis. 2016 Mar; 19(1):84-91. PMID: 26666409.
        View in: PubMed
      14. Grubman J, Barzi A. Lost in Translation: The Patient-Physician Relationship in the Molecular Era. J Palliat Med. 2015 Nov; 18(11):987-8. PMID: 26418297.
        View in: PubMed
      15. Grubman J, Barzi A. We Don't Know What We Don't Know About Adolescent and Young Adult Patients with Familial Adenomatous Polyposis-Related Colorectal Cancer. J Adolesc Young Adult Oncol. 2015 Sep; 4(3):105-7. PMID: 26421219; PMCID: PMC4575537.
      16. Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S, Sunakawa Y, Stremitzer S, Parekh A, Okazaki S, Berger MD, Barzi A, Lenz HJ. Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. Mol Cancer Ther. 2015 Oct; 14(10):2401-8. PMID: 26227487; PMCID: PMC4596790 [Available on 10/01/16].
      17. Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sunakawa Y, Sebio A, Yamauchi S, Matsusaka S, Parekh A, Barzi A, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ. Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases. Ann Oncol. 2015 Aug; 26(8):1728-33. PMID: 25957329; PMCID: PMC4511220.
      18. Barzi A, Sadeghi S, Kattan MW, Meropol NJ. Comparative effectiveness of screening strategies for Lynch syndrome. J Natl Cancer Inst. 2015 Apr; 107(4). PMID: 25794514; PMCID: PMC4402362.
      19. Barzi A, Lenz HJ. Cost-effectiveness of genomic testing for colorectal cancer: are we there yet? Oncology (Williston Park). 2015 Mar; 29(3):183-4; 186. PMID: 25783978.
        View in: PubMed
      20. Sunakawa Y, Wakatsuki T, Yang D, Zhang W, Ning Y, Stintzing S, Stremitzer S, Yamauchi S, Sebio A, El-khoueiry R, Iqbal S, Barzi A, Gerger A, Stotz M, Azuma M, Watanabe M, Koizumi W, Lenz HJ. Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients. Pharmacogenet Genomics. 2014 Dec; 24(12):588-96. PMID: 25203738; PMCID: PMC4218879.
      21. Sunakawa Y, Stremitzer S, Cao S, Zhang W, Yang D, Wakatsuki T, Ning Y, Yamauchi S, Stintzing S, Sebio A, El-Khoueiry R, Matsusaka S, Parekh A, Barzi A, Azuma M, Watanabe M, Koizumi W, Lenz HJ. Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer. Ann Oncol. 2015 Feb; 26(2):332-9. PMID: 25411415; PMCID: PMC4304380.
      22. Wakatsuki T, Stintzing S, Zhang W, Yang D, Azuma M, Ning Y, Yamauchi S, Matsusaka S, Volz NB, Sunakawa Y, Koizumi W, Watanabe M, Barzi A, El Khoueiry AB, Shah MA, Lenz HJ. Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent. Pharmacogenet Genomics. 2014 Nov; 24(11):539-47. PMID: 25203737; PMCID: PMC4190127.
      23. Semrad T, Barzi A, Lenz HJ, Hutchins IM, Kim EJ, Gong IY, Tanaka M, Beckett L, Holland W, Burich RA, Snyder-Solis L, Mack P, Lara PN. Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol. 2015 Jun; 20(3):518-24. PMID: 25091263; PMCID: PMC4318776.
      24. Barzi A, Thara E. Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment. Expert Opin Biol Ther. 2014 Sep; 14(9):1319-32. PMID: 24881691.
        View in: PubMed
      25. Yu S, Shabihkhani M, Yang D, Thara E, Senagore A, Lenz HJ, Sadeghi S, Barzi A. Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care. Clin Colorectal Cancer. 2013 Dec; 12(4):275-9. PMID: 24188686.
        View in: PubMed
      26. Barzi A, Lenz AM, Labonte MJ, Lenz HJ. Molecular pathways: Estrogen pathway in colorectal cancer. Clin Cancer Res. 2013 Nov 01; 19(21):5842-8. PMID: 23965904; PMCID: PMC3836673.
      27. Wakatsuki T, LaBonte MJ, Bohanes PO, Zhang W, Yang D, Azuma M, Barzi A, Ning Y, Loupakis F, Saadat S, Volz N, Stintzing S, El-Khoueiry R, Koizumi W, Watanabe M, Shah M, Stebbing J, Giamas G, Lenz HJ. Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States. Mol Cancer Ther. 2013 Oct; 12(10):2261-72. PMID: 23918832; PMCID: PMC3810398.
      28. Barzi A, Lenz HJ. Angiogenesis-related agents in esophageal cancer. Expert Opin Biol Ther. 2012 Oct; 12(10):1335-45. PMID: 22860627.
        View in: PubMed
      29. Sadeghi S, Barzi A, Kattan MW, Meropol NJ. Screening for Lynch syndrome in the general population-letter. Cancer Prev Res (Phila). 2011 Mar; 4(3):471; author reply 472. PMID: 21372042.
        View in: PubMed
      30. Barzi A, Sekeres MA. Myelodysplastic syndromes: a practical approach to diagnosis and treatment. Cleve Clin J Med. 2010 Jan; 77(1):37-44. PMID: 20048028.
        View in: PubMed
      31. Sadeghi S, Barzi A, Sadeghi N, King B. A Bayesian model for triage decision support. Int J Med Inform. 2006 May; 75(5):403-11. PMID: 16140572.
        View in: PubMed
      32. Sadeghi S, Barzi A, Smith JW. Ontology Driven Construction of a Knowledgebase for Bayesian Decision Models Based on UMLS. Stud Health Technol Inform. 2005; 116:223-8. PMID: 16160263.
        View in: PubMed
      33. Barzi A, Sadeghi S, King BR. Self-administered decision support tool for triage: results of a retrospective study. Stud Health Technol Inform. 2002; 85:45-51. PMID: 15458058.
        View in: PubMed
      34. Brutti A, Liberati AM, Biscottini B, Fatati G, Sini S, Barzi A, Grignani F. Combination chemotherapy with 5-fluorouracil and methyl-CCNU for the treatment of advanced gastrointestinal cancer. Tumori. 1979 Jun 30; 65(3):339-44. PMID: 462584.
        View in: PubMed